The UK Cystic Fibrosis Gene Therapy Consortium: Gene Therapy for Cystic Fibrosis Lung Disease

The UK Cystic Fibrosis Gene Therapy Consortium

Welcome to the UK CFGTC website. Our aim is to develop gene therapy for Cystic Fibrosis (CF).
For more information on Cystic Fibrosis please click here.

Multi-Dose Clinical Trial Funding: Latest News 18 November, 2011.

We are awaiting the outcome of our grant application to the NIHR EME Programme for funding of our Multi-Dose clinical trial. As soon as there is any firm news we will anounce here and on our Facebook page.

James Peckham ‘Rose of Hope’ Charity Bike Ride – w/c 21st November, 2011.

James Peckham from Southampton cycled 500 miles from London to Edinburgh via Oxford to raise money for the Cystic Fibrosis Trust Gene Therapy appeal. James is visited each of the UK CF Gene Therapy Consortium’s Research Centres on route to deliver a Rose of Hope. Find out more on our news page.
------------------------------------------------------------------------------------------------

The UKCFGTC is based at three of the UK's leading Universities, Edinburgh, Oxford and Imperial College London.

MRC Translational Research Award, Medical Futures Awards, June 2011.

Together against CF

In 2001 the UK's three UK's three leading Cystic Fibrosis gene therapy groups joined together as one organisation, the UKCFGTC, to share expertise and funding.

Aim

The aim of this collaboration was to bring the three research groups together to focus on a single common goal of making gene therapy for CF a clinical reality.

Progress

The Consortium is now the world's largest gene therapy group focused on a single disease, with a combined staff of over 50. Our clinical trial programme is well underway and there are plans to initiate a multi-dose study of our first clinical product in 2012.

This multi-dose trial will be the first ever opportunity to find out if our gene therapy can result in clinical benefit.

Unfortunately, this clinical study has been delayed due to a short-fall in funding. However, we are currently awaiting the outcome of our application to the Efficacy and Mechanism Evaluation (EME) Programme funded by the National Institute for Health Research (NIHR) and the Medical Research Council (MRC).

Research Highlights

Our Clinical Trial Programme

About the Consortium